

REMARKS

Claims 1 - 22 are now pending in the application. Claims 1 and 8 has been amended herein. No new matter has been introduced by virtue of the amendments made herein. In particular, the amendment to Claim 8 is supported by the specification as originally filed, for example, on p. 45, line 13, Example 32. The amendment to Claim 1 removes the definition of R_6 since R_6 is not defined in formula I, and limits the Markush groups of R_{22} and R_{23} . Accordingly, applicants respectfully request entry of the amendments. In view of the amendments and remarks made herein and in the Amendment file on April 28, 2003, applicants respectfully request reconsideration and withdrawal of the rejection set forth in the January 29, 2003 office action, and solicit the issuance of a notice of allowance. If a telephone interview is deemed to be helpful to expedite the prosecution of the subject application, the Examiner is invited to contact applicant's undersigned attorney at the telephone number provided.

Further to a telephone call made by Examiner T. N. Truong to Attorney for Applicants Andrea Dorigo, Applicants submit herein, without prejudice and in the interest of facilitating prosecution, a terminal disclaimer which overcomes the actual and provisional rejections of Claims 1, 6, 7, 9-11, and 17 under the judicially created doctrine of obviousness double patenting.

The Commissioner is hereby authorized to charge any fees required under 37 C.F.R. §§1.16 and 1.17 or to credit any overpayment to Deposit Account No. 16-1445.

Date: July , 2003

Andrea Dorigo
Attorney for Applicant(s)
Reg. No. 47,532

Pfizer Inc
Patent Department
150 East 42nd Street – 5th Floor
New York, NY 10017-5755
(212) 733-3381